It is however important to address that albeit the monoclonal BAFF antibody belimumab was approved for SLE treatment, having a low incidence of organ damage and an excellent safety profile, most of the other BAFF inhibitors were much less effective in clinical trials. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.